Centers | ||
|
|
|
EU-OPENSCREEN | Chulalongkorn University Drug Discovery and Drug Development Research Center (Chula4DR) | Chemical Genomics Facility at Purdue Institute for Drug Discovery |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
Chulalongkorn
Drug Discovery and Drug Development Research Center (Chula4DR) was
established in 2017, with the aim to facilitate advancement of academic
drug discovery and drug development research by leveraging innovations
and sciences... Read more |
The Chemical Genomics Facility is a core facility at Purdue Institute for Drug Discovery that provides expertise and resources needed in the early stage of drug discovery. The services include small molecule libraries, access to automated equipment... Read more |
Partnerships |
Events |
Jobs |
GSK and MD Anderson to co-develop new cancer therapeuticsGlaxoSmithkline and MD Anderson Cancer Center entered into a co-development and license agreement to develop antibody based therapeutics to treat cancer. Under this agreement MD Anderson grants exclusive rights to antibodies developed during the... View all Vanderbilt and Astra Zeneca to Develop New Drugs to Treat Psychosis and Other Brain DisordersUnder a new research collaboration agreement, Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) and Astra Zeneca will work together to develop compounds that act on M4 muscarinic acetylcholine receptor. The agreement entails research... View all Brigham & Woman's Hospital and Sanofi to Partner in Type 1 Diabetes SpaceSanofi and Brigham & Woman's Hospital an affiliate of Harvard University have entered into a joint collaboration to develop new drugs based on novel immunomodulatory approach to treat Type 1 Diabetes. Scientists from both groups will be... View all |
No EVENTS for listing |
No Job Posts |
